SLC5A2 and type 2 diabetes mellitus: At present, commercially available SGLT2 inhibitors include ipragliflozin, dapagliflozin, canagliflozin, empagliflozin, luseogliflozin, and tofogliflozin, which have been approved for use as antihyperglycemic agents in patients with T2DM [12].